THE COMBINATION OF IMGN632, A CD123-TARGETING ADC, WITH VENETOCLAX ENHANCES ANTI-LEUKEMIC ACTIVITY IN VITRO AND PROLONGS SURVIVAL IN VIVO IN PRE-CLINICAL MODELS OF HUMAN AML: PF201